๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
NCT06169449Endometrium Cancer
Peking University People's Hospital
Not applicable
240
Beijing
2022-04-01
Recruiting
The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception
NCT05085067Retained Products of Conception
Fu Xing Hospital, Capital Medical University
Not applicable
86
Beijing
2022-04-01
Recruiting
A National Registry on Chinese Patients With Cystic Fibrosis
NCT05289245Pulmonary Function
Peking Union Medical College Hospital
Observational
200
Beijing
2022-04-01
Recruiting
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
NCT05245474Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Phase 2
186
Beijing
2022-04-01
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
NCT05804916Breast Cancer, Optical Surface Monitoring Technology, Large-segment Radiotherapy
Peking Union Medical College Hospital
Phase 2/3
556
Beijing
2022-04-01
Not yet open
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
NCT05320874Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
232
Beijing
2022-04
Recruiting
Effect of Dexmedetomidine on Postoperative Delirium After Awake Craniotomies
NCT05195034Dexmedetomidine, Delirium, Awake Craniotomy
Beijing Tiantan Hospital
Not applicable
210
Beijing
2022-03-31
Active, closed
Olorofim Aspergillus Infection Study
NCT05101187Invasive Aspergillosis
F2G Biotech GmbH
Phase 3
225
Bengbu, Wuhan, Nanchang, Jinan, Shanghai, Xiaobailou, Wenzhou, Beijing
2022-03-31
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Recruiting
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
NCT05345860Early-stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing, Langfang
2022-03-24
Recruiting
Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement
NCT05739253Aortic Stenosis, Ascending Aortic Dilatation, Bicuspid Aortic Valve
China National Center for Cardiovascular Diseases
Observational
480
Beijing
2022-03-22
Active, closed
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
NCT05009069Rectal Neoplasms, Rectal Cancer
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
NCT06209320Myopia
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
777
Beijing
2022-03-15
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants โ‰ฅ16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
Sanofi
Phase 3
122
Beijing, Shanghai, Taiyuan, Zhengzhou
2022-03-11
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Active, closed
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
NCT06015230Lupus Erythematosus, Systemic
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2
136
Beijing
2022-03-08
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche
Phase 1
332
Beijing, Guangzhou, Nanchang, Tianjin
2022-03-07
Recruiting
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991Advanced Endometrial Cancer
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Recruiting
7.0T Magnetic Resonance Imaging Study of Parkinson's Disease
NCT06449404Parkinson's Diseases, MRI
Chinese PLA General Hospital
Observational
200
Beijing
2022-03-01
Recruiting
Comparison Between Prepectoral and Subpectoral Breast Reconstruction
NCT05833659Stage II Breast Cancer, Stage I Breast Cancer
Beijing Friendship Hospital
Observational
88
Beijing
2022-03-01
Recruiting
Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography
NCT05644548Hypertension, Diabetes Mellitus, Dyslipidemias
Beijing Tongren Hospital
Observational
300
Beijing
2022-03-01
Recruiting
THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein
NCT05194423Tricuspid Valve Regurgitation
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Beijing, Chengdu, Hangzhou, Shanghai
2022-03-01
Not yet open
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
NCT05287308Breast Cancer
Chinese Academy of Medical Sciences
Not applicable
500
Beijing
2022-03
Recruiting
Screening of Malignant Hyperthermia Susceptible Individuals
NCT05402839Malignant Hyperthermia
Peking University Third Hospital
Observational
50
Beijing
2022-02-22
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613Breast Cancer
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
NCT05285826Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Active, closed
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
NCT05393427Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
4
Beijing, Chongqing, Chengdu
2022-02-15
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
NCT05262491Gastrointestinal Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
Blood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease
NCT05232240Ischemic Cerebrovascular Disease, Blood Pressure Variability
Xuanwu Hospital, Beijing
Observational
300
Beijing
2022-02-14
Recruiting
Association Between Local Cerebral Oxygenation Monitoring and Postoperative Delirium in Carotid Endarterectomy
NCT05198635Cerebral Oxygen Saturation, Postoperative Delirium, Carotid Endarterectomy
Beijing Tiantan Hospital
Observational
140
Beijing
2022-02-14
Recruiting
Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCEโ„ข CORIโ„ข in Total Knee Arthroplasty (TKA) Procedure
NCT04848896Arthroplasty, Replacement, Knee
Smith & Nephew, Inc.
Not applicable
140
Beijing
2022-02-12
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316Solid Tumor, Advanced Solid Tumor
Impact Therapeutics, Inc.
Phase 1/2
61
Beijing
2022-02-11
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320Crohn's Disease (CD)
Takeda
Phase 3
120
Beijing, Zhengzhou, Shanghai, Hangzhou
2022-02-10
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
NCT07461831Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-02-01
Recruiting
Integrated Diagnosis and Treatment of CKD on Outcomes
NCT05242055Chronic Kidney Diseases, Hypertension, Hyperglycemia, Hyperlipidemias
Capital Medical University
Observational
1,000
Beijing
2022-02-01
Recruiting
Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission
NCT05015283Type2 Diabetes, Complication of Bariatric Procedure
Beijing Friendship Hospital
Not applicable
248
Beijing
2022-02-01
Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691HER2-positive Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Active, closed
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
NCT05241392Glioblastoma
Beijing Tiantan Hospital
Phase 1
30
Beijing
2022-01-27
Recruiting
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
NCT05139095Gestational Trophoblastic Neoplasia
Peking Union Medical College Hospital
Phase 2
70
Beijing
2022-01-27
Active, closed
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
NCT05353816End-stage Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xiโ€™an
2022-01-24
Recruiting
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
NCT05260385Digestive System Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1/2
133
Beijing, Bengbu, Chongqing, Fujian, Henan, Hubei, Shandong, Shanghai
2022-01-24
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Active, closed
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
NCT05118776Recurrent Glioblastoma
Ascletis Pharmaceuticals Co., Ltd.
Phase 3
136
Beijing
2022-01-21
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Recruiting
Treatment of Advanced and Metastatic Solid Tumors With MIL97
NCT04965077Advanced or Metastatic Solid Tumor
Beijing Mabworks Biotech Co., Ltd.
Phase 1
62
Beijing
2022-01-18
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
NCT06081478B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-01-18
Recruiting
Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease
NCT05337319Coronary Artery Disease
Beijing Anzhen Hospital
Observational
100,000
Beijing
2022-01-17
Recruiting
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT05851014Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Recruiting
A Phase โ…ข Study of Hemay022 in Combination With AI In Advanced Breast Cancer
NCT06313983Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd
Phase 3
339
Beijing
2022-01-08
Active, closed
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement
NCT07390513Aortic Valve Stenosis, Arrhythmia
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,000
Beijing
2022-01-01
Recruiting
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
NCT06598761Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma
Peking University First Hospital
Observational
60
Beijing
2022-01-01
Recruiting
A Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach
NCT07066475Spinal Cord Cancer, Spinal Cord Neoplasm, Spinal Cord Tumor
Beijing Tiantan Hospital
Observational
100
Beijing
2022-01-01
Recruiting
An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Disease
NCT06768008Congenital Heart Disease, Coarctation of Aorta, Aortic Stenosis, Pulmonary Atresia
Beijing Anzhen Hospital
Observational
10,000
Beijing
2022-01-01
By invitation
Pilot Study of BAO-G Technique in TAAA Endovascular Repair
NCT06534281Aortic Aneurysm, Thoracoabdominal
Peking Union Medical College Hospital
Phase EARLY_PHASE1
20
Beijing
2022-01-01
Recruiting
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
NCT06120374Urothelial Carcinoma
Peking University First Hospital
Observational
178
Beijing
2022-01-01
Recruiting
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
NCT05224934Soft Tissue Sarcoma, Retroperitoneal Sarcoma, Radiotherapy Side Effect, Ultra-hypofractionated Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2022-01-01
Recruiting
Cardiac Normal Values Assessed by Magnetic Resonance Imaging
NCT05346094Healthy Participants, Reference Values
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
938
Beijing
2022-01-01
Recruiting
Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
NCT06652022Oligometastatic Disease, Ureter Cancer, Renal Pelvic Carcinoma
Peking University First Hospital
Not applicable
102
Beijing
2022-01-01
Recruiting
Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
NCT05859659Brain (Nervous System) Cancers, Glioma, Brain Tumor
Yaou Liu
Observational
70,000
Beijing
2022-01-01
Recruiting
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
NCT05330923Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis, HIV/AIDS
Peking Union Medical College Hospital
Observational
2,000
Beijing
2022-01-01
Recruiting
A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype
NCT06621056Asthma Exacerbations
Peking University Third Hospital
Observational
300
Beijing
2022-01-01
Recruiting
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
NCT05408897Gastrointestinal Stromal Tumors, Minimal Residual Disease
Peking University People's Hospital
Observational
45
Beijing
2022-01-01
Recruiting
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
NCT05426720Pulmonary TB
Peking University Third Hospital
Observational
400
Beijing
2022-01-01
Recruiting
Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
NCT06572085Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
Tang Ziren
Phase 4
350
Beijing
2022-01-01
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Phase 1
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
Recruiting
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
NCT04662918GastroIntestinal Bleeding
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Recruiting
Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI
NCT05400967177Lu-EB-FAPI
Peking Union Medical College Hospital
Phase EARLY_PHASE1
10
Beijing
2022-01-01
Recruiting
Radical Radiotherapy Versus Radical Surgery for UTUC
NCT06652009Renal Pelvis Cancer
Peking University First Hospital
Observational
60
Beijing
2022-01-01
Not yet open
Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
NCT05169021Cerebral Small Vessel Diseases, Stroke
Beijing Tiantan Hospital
Phase 4
15,000
Beijing
2021-12-31
Recruiting
Effect of RT3D-TEE-guided Mitral Valve Repair on Outcomes in Patients With Degenerative Mitral Valve Disease
NCT05595226Degenerative Mitral Valve Disease
Sheng Liu
Not applicable
338
Beijing
2021-12-31
Recruiting
ACOART BTK RENEW๏ผšA Post Market Clinical Study
NCT04885985Peripheral Artery Disease
Acotec Scientific Co., Ltd
Not applicable
107
Beijing
2021-12-31
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Active, closed
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
NCT05167071Solid Tumors, Neuroendocrine Tumors, CRC
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1
53
Beijing
2021-12-28
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Rows per page Showing 4701–4800 of 5484
Previous 46 47 48 49 50 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=48

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.